Coming up soon, Copenhagen will be the center of health economics as more than five thousand pharmaceutical and healthcare professionals gather for the ISPOR conference. ISPOR has been well known, especially among health economists. However, this years’ top trends real-world data (RWD) and real-world evidence (RWE) attract even wider audience.
Medaffcon has added Swedish healthcare registries to its capabilities as it continues to pursue growth and facilitate data utilisation by providing pharmaceutical companies access to rich and relevant healthcare data.
Timo Karvinen joined Medaffcon’s Market Access team as an expert in the beginning of May. In addition to his extensive expertise, he also brings a whole new service concept to Medaffcon.
The Market Access team works actively with different actors, while helping customers in processes related to market access and market presence and in strategic planning.
Heini Honkanen has been appointed as Medaffcon’s Market Access Lead. The new Market Access Team was created when the previous Price and Reimbursement and HE & Access Teams were merged.
Medaffconin Tanja Nieminen ja Heini Honkanen osallistuivat terveystaloustieteen tutkimukseen ja terveydenhuollon menetelmien arviointiin keskittyvään ISPOR-kongressiin marraskuussa.
In health economic studies, real world evidence (RWE) can produce additional knowledge, especially on the...
We already have clinical medicine trials. Why on earth do we also need real world...
RWE or real-world evidence provides authorities assessing pharmacotherapies with data on the prevalence of a...
Health economic evaluations bring additional information to the authorities’ decision-making concerning medicinal products. How does...
From the perspective of decision-making, it is important that a health economic evaluation conducted on...
HUS Pharmacy Director Kerstin Carlsson reveals the process of national price negotiation of hospital-only medicinal...
OSLO, Norway/ ESPOO, Finland May 24, 2021 LINK Medical, the Northern European clinical research organization...
Medicines in Finland are divided into medicines in ambulatory and hospital care. This article describes...
Pricing and reimbursement in Finland Pharmaceuticals Pricing Board (PPB), operating under the Ministry of Social...
Public health authorities and pharmaceutical companies have searched for alternative funding formulas to share the...
Demonstrating that a health technology, e.g. a product, procedure or any intervention, is worth its...
Risk-sharing agreements (RSA) are one of the most interesting and debated topics in the Finnish...
Learn about conditional reimbursement from the interview with CEO Jarmo Hahl, Medaffcon Oy. There’s often...
Like already mentioned in my previous post it is known that different Risk-Sharing Models have...
As we all know different Risk-Sharing Models (RSM) have been varyingly in use in different...
Pharma Industry Finland commissioned a report from Medaffcon concerning how effectiveness could be assessed in...
In our customer event in April, we examined risk-sharing models from three different perspectives. Director...
The assessment of treatment effectiveness should hold a central role in healthcare, in order to...
The precondition for a medicinal product to receive a marketing authorisation is that the product...
Summary of Miia Turpeinen’s speech: Miia Turpeinen, Senior Medical Officer at Oulu University Hospital catchment...